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Dengue is a major international public health concern. There is no drug to treat dengue virus infections
and a vaccine is yet to be licensed. The laboratory diagnosis of dengue virus infection has been greatly
improved during the last decade; therefore, the main limiting factor is the production of recombinant
viral antigens on a large scale. Domain III of dengue virus envelope protein contains multiplex conforma-
tion-dependent neutralizing epitopes, making it an attractive diagnostic candidate. In this work, we have
demonstrated the expression of dengue virus type 1 envelope domain III protein (EDIII-D1) in methylo-
trophic yeast, Pichia pastoris GS115. The recombinant secreted protein (sEDIII-D1) was puriﬁed by afﬁnity
chromatography and characterized by SDS–PAGE. Puriﬁed protein was recognized in immunoblot anal-
ysis and enzyme-linked immunosorbent assay (ELISA) with dengue-infected human serum samples. In
conclusion, secreted expressions of domain III protein can be obtained in P. pastoris by methanol induc-
tion. This product has the potential to be used for the diagnosis of dengue infections.
 2013 Elsevier Inc. All rights reserved.Introduction
Dengue is one of the most serious mosquito-borne ﬂavivirus
diseases. Dengue fever (DF)2 can be caused by any of four serotypes,
dengue virus type 1, 2, 3, and 4 (DENV-1, DENV-2, DENV-3 and
DENV-4) [1]. People living in tropical and subtropical areas are at
risk of dengue virus infection. The World Health Organization esti-
mates that there may be 100 million cases of dengue infections
worldwide every year, which result in 250,000–500,000 severe cases
(dengue hemorrhagic fever [DHF]/dengue shock syndrome [DSS])
and approximately 25,000 fatalities [2,3]. There is no speciﬁc treat-
ment for DF. Diagnosis of acute dengue virus infection on the basis
of clinical syndromes is not reliable and, therefore, laboratory stud-
ies are normally relied upon to conﬁrm diagnoses because more than
half of infected individuals either are asymptomatic or have mild
undifferentiated fevers [4].
DENV is a single-stranded RNA virus. The dengue virion has
three structural proteins (capsid [C], envelope [E], and membrane[M]) and RNA codes for seven nonstructural proteins. The envelope
of the DENV consists of a lipid bilayer containing two envelope-
associated proteins: the E and M proteins; the glycoprotein E has
three domains (I, II and III) [5]. Domain III (EDIII) contains approx-
imately 100 amino acid (aa) residues, which are stabilized by a sin-
gle S–S; it, therefore, lacks glycosylation sites. EDIII can fold
independently into an immunoglobulin-like module which under-
goes the most signiﬁcant displacement in fusion transition [3,6,7].
Structural studies of intact virions have shown that EDIII is ex-
posed and accessible on the virion surface [8]. This domain, which
is responsible for receptor binding, contains multiple type and sub-
type speciﬁc neutralizing epitopes [3,9,10]. Furthermore, recombi-
nant EDIII protein [11,12] and EDIII-speciﬁc mAbs [13] can block
virus infectivity. EDIII is, therefore, an important candidate as a re-
agent for rapid viral diagnosis because nowadays the greatest cur-
rent difﬁculty in conducting immunoenzymatic assays is obtaining
suitable antigens. In Brazil, the antigens currently used for dengue
diagnosis are structural viral proteins taken from the brains of arti-
ﬁcially infected new-born mice, which is an arduous and expensive
method. This is an important obstacle in the large-scale production
of antigens used in diagnostic assays of infected patients. Commer-
cially available kits using recombinant proteins or viruses have
been used in routine dengue laboratory diagnosis, but are expen-
sive. Worldwide, conducting rapid and inexpensive diagnostic tests
is increasingly necessary to allow diagnoses on a larger scale, even
in the remote outskirts of large cities. Due to this demand,
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are being made using a heterologous system of protein expression
in Eukaryotes.
In the last several years, the methylotrophic yeast Pichia pastoris
has emerged as a powerful and inexpensive heterologous system
for the production of high levels of functionally active recombinant
proteins [14,15]. As a eukaryote, P. pastoris provides the potential
for producing soluble correctly folded recombinant proteins that
have undergone all of the post-translational modiﬁcations required
for functionality [16]. Several S–S-linked proteins such as recombi-
nant hepatitis B surface antigen and insulin have been successfully
produced in P. pastoris [17–19].
In this study, we expressed the optimized gene encoding pro-
tein E domain III of DENV-1 in P. pastoris GS115. This system per-
mits secretion of the recombinant protein (sEDIII-D1) into the
culture supernatant, free of toxins/pyrogens (unlike Escherichia coli
derived proteins). The puriﬁed protein has shown immunogenic
potential.Materials and methods
Microbial host strains and plasmid vector
The host strain used in this study was P. pastoris GS115. This
strain is defective in the histidine dehydrogenasegene (his4) and
has a functional copy of the alcohol oxidase 1 gene (AOX1). For
secretory expression in this yeast, we used the integrative plasmid
pPICZaA, which contains an AOX1 promoter fused to the Saccharo-
myces cerevisiae pre-pro a factor secretory signal-encoding se-
quence and a zeocin-resistance marker for selection of yeast
transformants. P. pastoris GS115 strain, plasmid pPICZaA, and
E. coli DH5a used for cloning and replication of the construction
were purchased from Invitrogen, Carlsbad, CA.
Creation of recombinant P. pastoris clone carrying EDIII-D1 gene
A 408 base-pair (bp) EDIII-dengue 1 gene (GenBank accession
number NC_923865), codon optimized for expression in P. pastoris,
was obtained by chemical synthesis (Genscript, NJ, USA). This gene
was inserted into the EcoR I and Not I restriction sites of pPICZaA.
The resultant construct, pPICZEDIII-D1, was linearized with Sac I
and electroporated into P. pastoris GS115. In parallel, we also gen-
erated a blank control clone, harboring the empty parent vector.
Zeocin-resistant high-copy transformants were selected on yeast
extract peptone dextrose sorbitol (YPDS) plates containing zeocin
(100, 200, and 500 lg/ml), as described in the Invitrogen Easy
select TMPichia expression kit manual. (Invitrogen’s Easy Select
Pichia Expression kit manual). The presence of the EDIII-D1 gene
insert was analyzed by direct colony PCR using a domain III-spe-
ciﬁc primer pair (Sense 50-tcacaagaaggtgccatgcac-30; Antisense
50-agacaacttcaaagccttttc-30).
Production of sEDIII-D1 recombinant protein
A veriﬁed transformant was inoculated in 5 mL YPD medium to
a starter culture and maintained for 24 h at 30 C in a shaker. This
pre-culture was inoculated into 1L BMGY pH 6.0 (1% yeast extract,
2% peptone, 1.34% yeast nitrogen base, 0.002% biotin, 100 mM
sodium phosphate, 1% glycerol and 0.004% histidine). The culture
was allowed to shake at 250 rpm at 30 C for approximately 3 days,
until it reached an OD600 of approximately 20. At this point, cells
were pelleted by low-speed centrifugation, washed with sterile
peptoned water (1% yeast extract, 2% peptone), and re-suspended
in 100 mL BMMY pH 6.0 (1% yeast extract, 2% peptone, 1.34% yeast
nitrogen base, 0.002% biotin, 100 mM sodium phosphate, 1%methanol and 0,004% histidine) to induce protein expression.
Induction was maintained for 72 h at 250 rpm/30 C; methanol
was added to a ﬁnal concentration of 1% (v/v) at 12 h intervals.
After the induction, the supernatants were collected by centrifuga-
tion and processed for the sEDIII-D1 puriﬁcation.
Puriﬁcation and characterization of recombinant protein sEDIII-D1
The culture supernatant containing sEDIII-D1 protein was
freshly diluted with an equal volume of binding buffer pH 8.0
(20 mM sodium phosphate, 500 mM NaCl) and clariﬁed by ﬁltra-
tion through a 0.45 lm membrane, and then subjected to afﬁnity
chromatography. The clariﬁed supernatant was loaded into a
1 ml HisTrap FF crude column, previously equilibrated with bind-
ing buffer, and attached to an AKTA puriﬁer system (GE Healthcare
Life Sciences, Uppsala, Sweden). A ten-column volume of binding
buffer was passed through the column to remove non-speciﬁcally
bound proteins and the speciﬁcally bound protein was retrieved
from the column using an elution buffer (20 mM sodium phos-
phate, 500 mM NaCl, 300 mM Imidazole). Peak fractions were
pooled together and dialyzed against PBS pH 8.0 using centrifugal
ﬁltration devices with a 10,000-molecular weight cut-off (Milli-
pore); the protein estimation was determined with a BCA kit
(Pierce Chemical Co., Rockford, USA). For characterization, the puri-
ﬁed proteins were subjected to 15% SDS–PAGE. Separated proteins
were electro-transferred onto a nitrocellulose membrane and pro-
cessed for immunoblot analysis using anti-HisTag mAb (Sigma,
USA) and dengue-infected human serum samples.
Serum samples
Sera from 171 patients were provided by the Central Public
Healthcare Laboratory in the State of Rondônia (LACEN/RO) and
the Central Blood Bank of Rondônia State, Brazil (FHEMERON/RO).
All sera were tested in accordance with protocols approved by
the Central Blood Bank of Rondônia State, Brazil Institutional
Human/Animal Care and Use Committee, and all samples were
anonymous.
The samples had previously been conﬁrmed as IgM or IgG posi-
tive for dengue by MAC-ELISA IgM (Pan-Bio, Australia) and Dengue
Duo IgM and IgG ELISA Capture Kits (Sanoﬁ, NJ, USA). Of the 171
samples, 60 were IgG positive and 32 were IgG negative using Den-
gue Duo IgM and IgG ELISA Capture Kits; 50 were IgM positive and
29 were IgM negative using both kits MAC-ELISA IgM (Pan-Bio,
Australia) and Dengue Duo IgM and IgG ELISA Capture Kits (Sanoﬁ,
NJ, USA).The totals were 110 positive and 61 negative samples.
Indirect enzyme-linked immunosorbent assay (ELISA) for detection of
IgM and IgG
Puriﬁed sEDIII-D1 were used as a coating antigen for sensitiza-
tion (1.0 lg/well) of 96-well polystyrene plates (Maxisorp; Nunc,
Roskilde, Denmark) in a carbonate–bicarbonate buffer (pH 9.6)
and incubated at 4 C overnight. The plates were blocked for
30 min with block solution (PBS/5% fetal bovine serum). Serum
samples were diluted 1/100 in block solution; 100 lL of each ser-
um dilution was assayed in duplicate. The plates were incubated
at 37 C for 2 h and washed four times with PBS/1% Tween 20. Sec-
ondary anti-human IgM or IgG antibodies peroxidase-conjugated
(Sigma, USA) was diluted 1/2500 in block solution added to the
plates, which were incubated at 37 C for 2 h, followed by ﬁve
washes;100 lL of TMB (Sigma, USA) substrate solution (1 tablet
TMB, 10 mL of 0.05 M phosphate–citrate buffer/pH 5.0, 2 lL of
hydrogen peroxide) was then added. Plates were then incubated
at room temperature for 20 min and the reaction was stopped with
50 lL of 2 M H2SO4. The plates were read with a multichannel
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450 nm ﬁlter.
Statistical analysis
Receiver operating characteristic (ROC) curves were analyzed to
estimate the diagnostic cut off, sensitivity, and speciﬁcity (INSTAT
software, GraphPad, San Diego, CA, USA).
Results
Creation of a recombinant P. pastoris clone expressing EDIII-D1
To create an EDIII-D1 secretory P. pastoris clone, we constructed
an expression vector pPICZEDIII-D1 (Fig. 1B) by inserting a codon-
optimized synthetic gene (Fig. 1A) into the plasmid pPICZaA. In
this system, protein expression is under the control of the AOX1
promoter in response to methanol induction. The EDIII-D1 se-
quence was fused in frame to the S. cerevisiae pre-pro a-factor
secretory signal and integrated into the genome of the P. pastoris
host strain GS115 using the single cross-over strategy.
The recombinant protein EDIII of DENV-1 encoded in this
system is composed of 138 amino acid residues; these domains
possess the single S–S bond that is critical for structural and anti-
genic integrity [20]. The EDIII-D1 is predicted to be 14,5 kDa in
size and was expressed as fusions to a C-terminal polyhistidine
(6xHis) tag to aid in detection and puriﬁcation.
Transformants harboring the EDIII-D1 expression cassette were
selected in the presence of 500 lg/mL zeocin, and then the pres-
ence of the integrated EDIII-D1 gene was further conﬁrmed by di-
rect colony PCR (Fig. 2A). A DNA fragment of about 400 bp was
ampliﬁed from transformed GS115 cells, using speciﬁc an EDIII-
D1 primer pair. The ampliﬁcation with AOX1 primers conﬁrmed
that the domain gene had been integrated into the AOX1 locus
on the genome of the P. pastoris GS115 host.Fig. 1. The envelope domain III from dengue-1 antigen expression. (A) Codon-
optimized synthetic gene of EDIII-D1. (B) Map of plasmid pPICZ-EDIII-D1. The EDIII-
D1 gene was inserted into the EcoR I and Not I sites of the integrative vector
pPICZaA under the control of the methanol-inducible AOX1 promoter (50 AOX1). (C)
Recombinant protein sequence.A PCR-conﬁrmed clone was assayed for the expression of EDIII-
D1 gene product in small-scale testing with methanol induction for
3 days. Secreted expression of the recombinant protein is indicated
by a 15 kDa protein band corresponding to the expected molecular
weight of EDIII-D1 in the supernatant fraction (Fig. 2B). No similar
band appeared in the blank control or in the supernatant without
methanol induction. After conﬁrmation of the secretion, this pro-
tein was called sEDIII-D1. Expression of the sEDIII-D1 protein
was obtained during the ﬁrst 24 h; therefore, induction with meth-
anol for 3 days resulted in the maximal sEDIII-D1 expression
(Fig. 2C). A nonspeciﬁc band of approximately 70 kDa, can also
be observed in the material after methanol induction, but this band
was not revealed in Western blot analysis (Fig. 3B and C).
Expression and puriﬁcation of recombinant sEDIII-D1
The expression of recombinant sEDIII-D1 was done in condi-
tions developed by Barr and collaborators that closely resembled
the requirements of fermentor systems [21]. Therefore, the culture
was conducted in two stages, ﬁrst via the generation of biomass
in a repressive buffered media, and then by the production phase,
where the cells were re-suspended in small volumes of methanol
induction-buffered media. The use of a buffered medium (pH
3.0–6.0) is known signiﬁcantly reduce the proteolysis of the
secreted recombinant protein [22,23].
Since the recombinant sEDIII-D1 protein contains a polyhisti-
dine tag, it was recovered from the clariﬁed methanol-induced
supernatant by Ni-afﬁnity chromatography. The entire process of
puriﬁcation was controlled and monitored by connecting the col-
umn to an AKTA system. Aliquots of fractions collected during
the puriﬁcation were analyzed by SDS–PAGE (Fig. 3A). It is evident
that the bound fraction contains a major band of 15 kDa which is
consistent with the predicted size of the sEDIII-D1 protein. An
immunoblot analysis of the puriﬁed protein using anti-HisTag
mAb and dengue positive serum appeared to conﬁrm its identity
(Fig. 3B and C). These data were conﬁrmed by high sensitivity
and speciﬁcity of IgM anti-dengue using sEDIII-D1 (Table 1).
Indirect ELISA for the detection of IgM and IgG anti-dengue
A panel of the 160 serum samples was evaluated with the puri-
ﬁed and characterized sEDIII-D1 with an indirect enzyme-linked
immunosorbent assay (ELISA); they were used to evaluate IgM
and IgG anti-dengue. These samples had previously been charac-
terized by commercially available serological tests (114 positive
and 46 negative). For the IgM anti-dengue, the cut-off was deﬁned
at the point at which 0.204 nm, 99.12% speciﬁcity, and 86.96% sen-
sitivity were observed. Therefore, the cut-off for IgG anti-dengue
was 0.300 nm, 65.25% speciﬁcity, and 86.67% sensitivity (Fig. 4,
Table 1).Discussion
The global prevalence of dengue has grown dramatically in re-
cent decades. This viral disease affects people in tropical and sub-
tropical regions around the world, predominantly in urban and
semi-urban areas, threatening more than 2.5 billion [24]. In ende-
mic areas, secondary infections are most common and more highly
associated with mortality [25,26]. Therefore, there is genuine de-
mand for the rapid detection and differentiation of dengue virus
infection diagnostic assays.
The dengue viral envelope protein is responsible for viral
attachment by binding to cellular receptors [27,28]. Hence, the
Ig-like envelope domain III protein, an independently folding do-
main that plays an important role in host receptor interactions,
Fig. 2. Construction of P. pastoris expressing EDIII-D1 recombinant protein. (A) PCR ampliﬁcation of AOX1 gene (AOX1) or dengue-1 domain III genes (EDIII) from two
representative zeocin-resistant GS115transformants, C negative control. (B) SDS–PAGE analysis of protein expression in the supernatant (BC) Blank control (GS115), (Ind)
supernatant without induction, and (Ind+) supernatant after methanol induction. (C) SDS–PAGE analysis of recombinant protein expression after 1, 2, and 3 days of methanol
induction. (MW) Protein molecular weight markers (kDa).
Fig. 3. Puriﬁcation and characterization of the sEDIII-D1 protein. (A) Comassie
blue-stained 15% reduced SDS–PAGE of samples obtained from each of the
recombinant protein puriﬁcation steps. (1) Total supernatant after methanol
induction; (2) sample that did not interact with the afﬁnity medium; (3) puriﬁed
recombinant sEDIII-D1; (MW) Protein molecular weight markers (kDa). (B)
Immunoblot of sEDIII-D1 after the puriﬁcation. Aliquots of the puriﬁed material
(3) were transferred to nitrocellulose and probed with anti-HisTag antibodies and
dengue positive serum. (M) Pre-stained molecular weight markers (kDa). The
arrows indicate the electrophoretic positions of the sEDIII-D1 protein.
Table 1
Sensitivity and speciﬁcity of IgM and IgG anti-dengue using sEDIII-D1. Receiver
operating characteristic (ROC) curves were analyzed to estimate the diagnostic
sensitivity and speciﬁcity.
% Sensitivity % Speciﬁcity
IgM 86.96 99.12
IgG 86.67 65.25
12 S.A. Cardoso et al. / Protein Expression and Puriﬁcation 92 (2013) 9–13containing multiple serotype-speciﬁc conformation-dependent
neutralizing epitopes [12,29] and exhibiting a very high degree of
stability [30,31], has become an attractive candidate as a reagent
for diagnosis of dengue infections.
During the last years, successful expressions of recombinant
envelope protein dengue viruses have been demonstrated in differ-
ent vector systems [32–34]. Although prokaryotic expression sys-
tems such as E. coli are simple to perform, they lack the
modiﬁcation mechanism of eukaryotic expression and it is difﬁcult
to purify recombinant proteins from inclusion bodies. The baculo-
virus expression system is usually used to produce recombinant
proteins in eukaryotic cells, but they are not suitable for large-scale
expression of foreign proteins. In the present study, the P. pastoris
yeast expression system was used to produce dengue virus type 1domain III proteins because of the simplicity of techniques needed
for molecular genetic manipulation and its ability to produce for-
eign proteins extra cellularly. Furthermore, many post-transla-
tional modiﬁcations of eukaryotic systems, such as disulﬁde bond
formation, can be performed in the yeast system. The recombinant
vector pPICZEDIII-D1 described above was constructed with the
EDIII-D1 gene in frame downstream from the sequence encoding
the S. cerevisiae a signal peptide and upstream from the sequence
encoding His-tag.
In accordance with the above objective, we demonstrated the
secretory expression of the sEDIII-D1 protein in a two-phase culti-
vation, which included a glycerol batch phase, to accumulate bio-
mass followed by an induction phase with methanol. The
secretion of the recombinant protein into the growth medium is
an important advantage because only low levels of endogenous pro-
tein are secreted to themedia by the yeast itself, a process that facil-
itates following the protein puriﬁcation steps [35,36]. The sEDIII-D1
recombinant protein was puriﬁed in Ni-afﬁnity column chromatog-
raphy and characterized by its electrophoreticmobility and its reac-
tivity to 6xHis Tag mAbs and dengue-positive human serum.
Further puriﬁed and characterized sEDIII-D1 was successfully
tested for the diagnosis of dengue infection in an indirect ELISA.
From the 100 total human serum samples, the sensitivity was
86.67% and speciﬁcity 65.25% for IgG; sensitivity was 86.96% and
speciﬁcity was 99.12% for IgM. The immunodominant epitopes
preserved in the recombinant sEDIII-D1 protein certainly contrib-
uted to a high degree of sensitivity and speciﬁcity for the diagnosis
of dengue infections. The common problem with dengue serologi-
cal assays lies in detection of circulating cross-reactive antibodies
against other Flaviviruses. Cross-reactivity was found to be mini-
mum while identifying dengue virus infection, with in-house indi-
rect ELISA employing pre-coated EDIII-D1 proteins.
Fry and collaborators reported that ideal results are obtained by
combining antigen or antibody detection methods, thereby
increasing the sensitivity and the speciﬁcity of serological tests
[37]. Previous research indicates that variables such as infecting
serotype, primary or secondary infection, time of sample collec-
tion, and the individual responses of patients are factors that can
cause variations in the sensitivity and speciﬁcity of serological
tests from 65% to 100% [3,37,38]. The sensitivity and speciﬁcity
of sEDIII-D1 proteins in detecting antibodies from dengue-infected
patients renders hope that it may be a promising candidate for the
development of commercial and inexpensive dengue diagnostic
kits. A similar strategy could lead to the production of recombinant
domain III proteins of other serotypes. The level of puriﬁcation
facilitated by protein secretion has the potential to make this a
highly cost-effective approach for dengue diagnosis, in a large scale
production.
Fig. 4. Indirect ELISA using sEDIII-D1. Results of dengue-positive and negative (healthy individuals) samples in IgM (A) and IgG (B) detection. The horizontal line indicates the
cutoff value of the assay.
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